Meriva® ||| S:0 E:7 ||| NNP
,  ||| S:7 E:9 ||| ,
a  ||| S:9 E:11 ||| DT
lecithinized  ||| S:11 E:24 ||| JJ
curcumin  ||| S:24 E:33 ||| JJ
delivery  ||| S:33 E:42 ||| NN
system ||| S:42 E:48 ||| NN
,  ||| S:48 E:50 ||| ,
in  ||| S:50 E:53 ||| IN
the  ||| S:53 E:57 ||| DT
control  ||| S:57 E:65 ||| NN
of  ||| S:65 E:68 ||| IN
benign  ||| S:68 E:75 ||| JJ
prostatic  ||| S:75 E:85 ||| JJ
hyperplasia ||| S:85 E:96 ||| NN
:  ||| S:96 E:98 ||| :
a  ||| S:98 E:100 ||| DT
pilot ||| S:100 E:105 ||| NN
,  ||| S:105 E:107 ||| ,
product  ||| S:107 E:115 ||| NN
evaluation  ||| S:115 E:126 ||| NN
registry  ||| S:126 E:135 ||| NNS
study  ||| S:135 E:141 ||| VBP
The  ||| S:141 E:145 ||| DT
aim  ||| S:145 E:149 ||| NN
of  ||| S:149 E:152 ||| IN
this  ||| S:152 E:157 ||| DT
registry  ||| S:157 E:166 ||| JJ
evaluation  ||| S:166 E:177 ||| NN
study  ||| S:177 E:183 ||| NN
was  ||| S:183 E:187 ||| VBD
to  ||| S:187 E:190 ||| TO
compare ||| S:190 E:197 ||| VB
,  ||| S:197 E:199 ||| ,
in  ||| S:199 E:202 ||| IN
symptomatic  ||| S:202 E:214 ||| JJ
BPH  ||| S:214 E:218 ||| NN
patients ||| S:218 E:226 ||| NNS
,  ||| S:226 E:228 ||| ,
two  ||| S:228 E:232 ||| CD
management  ||| S:232 E:243 ||| NN
plans  ||| S:243 E:249 ||| VBZ
based  ||| S:249 E:255 ||| VBN
on  ||| S:255 E:258 ||| IN
a  ||| S:258 E:260 ||| DT
currently  ||| S:260 E:270 ||| RB
validated  ||| S:270 E:280 ||| JJ
standard  ||| S:280 E:289 ||| JJ
treatment  ||| S:289 E:299 ||| NN
[ ||| S:299 E:300 ||| -LRB-
defined  ||| S:300 E:308 ||| VBN
as  ||| S:308 E:311 ||| IN
the  ||| S:311 E:315 ||| DT
best  ||| S:315 E:320 ||| RBS
standard  ||| S:320 E:329 ||| JJ
management  ||| S:329 E:340 ||| NN
( ||| S:340 E:341 ||| -LRB-
BSM ||| S:341 E:344 ||| NNP
) ||| S:344 E:345 ||| -RRB-
]  ||| S:345 E:347 ||| -RRB-
including  ||| S:347 E:357 ||| VBG
or  ||| S:357 E:360 ||| CC
not  ||| S:360 E:364 ||| RB
curcumin  ||| S:364 E:373 ||| JJ
( ||| S:373 E:374 ||| -LRB-
administered  ||| S:374 E:387 ||| VBN
as  ||| S:387 E:390 ||| IN
Meriva® ||| S:390 E:397 ||| CD
)  ||| S:397 E:399 ||| -RRB-
as  ||| S:399 E:402 ||| IN
a  ||| S:402 E:404 ||| DT
further  ||| S:404 E:412 ||| JJ
complementary  ||| S:412 E:426 ||| JJ
adjuvant  ||| S:426 E:435 ||| JJ
element ||| S:435 E:442 ||| NN
.  ||| S:442 E:444 ||| .
Signs  ||| S:444 E:450 ||| NNS
and  ||| S:450 E:454 ||| CC
symptoms  ||| S:454 E:463 ||| NNS
were  ||| S:463 E:468 ||| VBD
evaluated  ||| S:468 E:478 ||| VBN
using  ||| S:478 E:484 ||| VBG
the  ||| S:484 E:488 ||| DT
International  ||| S:488 E:502 ||| NNP
Prostate  ||| S:502 E:511 ||| NNP
Symptom  ||| S:511 E:519 ||| NNP
Score  ||| S:519 E:525 ||| NNP
( ||| S:525 E:526 ||| -LRB-
IPSS ||| S:526 E:530 ||| NNP
) ||| S:530 E:531 ||| -RRB-
.  ||| S:531 E:533 ||| .
SUBJECTS ||| S:533 E:541 ||| NNS
,  ||| S:541 E:543 ||| ,
METHODS ||| S:543 E:550 ||| NNP
:  ||| S:550 E:552 ||| :
The  ||| S:552 E:556 ||| DT
study  ||| S:556 E:562 ||| NN
was  ||| S:562 E:566 ||| VBD
carried  ||| S:566 E:574 ||| VBN
out  ||| S:574 E:578 ||| RP
on  ||| S:578 E:581 ||| IN
a  ||| S:581 E:583 ||| DT
total  ||| S:583 E:589 ||| NN
of  ||| S:589 E:592 ||| IN
61  ||| S:592 E:595 ||| CD
subjects.  ||| S:595 E:605 ||| CD
33  ||| S:605 E:608 ||| CD
subjects  ||| S:608 E:617 ||| NNS
( ||| S:617 E:618 ||| -LRB-
mean  ||| S:618 E:623 ||| JJ
age  ||| S:623 E:627 ||| NN
58.6 ||| S:627 E:631 ||| CD
; ||| S:631 E:632 ||| :
5.3 ||| S:632 E:635 ||| CD
)  ||| S:635 E:637 ||| -RRB-
completed  ||| S:637 E:647 ||| VBD
the  ||| S:647 E:651 ||| DT
survey  ||| S:651 E:658 ||| NN
with  ||| S:658 E:663 ||| IN
at  ||| S:663 E:666 ||| IN
least  ||| S:666 E:672 ||| JJS
24  ||| S:672 E:675 ||| CD
weeks  ||| S:675 E:681 ||| NNS
of  ||| S:681 E:684 ||| IN
treatment  ||| S:684 E:694 ||| NN
with  ||| S:694 E:699 ||| IN
Meriva®  ||| S:699 E:707 ||| CD
in  ||| S:707 E:710 ||| IN
association  ||| S:710 E:722 ||| NN
with  ||| S:722 E:727 ||| IN
the  ||| S:727 E:731 ||| DT
BSM ||| S:731 E:734 ||| NNP
.  ||| S:734 E:736 ||| .
The  ||| S:736 E:740 ||| DT
BSM-alone  ||| S:740 E:750 ||| JJ
control  ||| S:750 E:758 ||| NN
group  ||| S:758 E:764 ||| NN
consisted  ||| S:764 E:774 ||| VBD
of  ||| S:774 E:777 ||| IN
28  ||| S:777 E:780 ||| CD
volunteers  ||| S:780 E:791 ||| NNS
of  ||| S:791 E:794 ||| IN
similar  ||| S:794 E:802 ||| JJ
age  ||| S:802 E:806 ||| NN
( ||| S:806 E:807 ||| -LRB-
58.4  ||| S:807 E:812 ||| CD
years ||| S:812 E:817 ||| NNS
; ||| S:817 E:818 ||| :
3.4 ||| S:818 E:821 ||| CD
)  ||| S:821 E:823 ||| -RRB-
and  ||| S:823 E:827 ||| CC
severity  ||| S:827 E:836 ||| NN
of  ||| S:836 E:839 ||| IN
the  ||| S:839 E:843 ||| DT
condition ||| S:843 E:852 ||| NN
.  ||| S:852 E:854 ||| .
The  ||| S:854 E:858 ||| DT
range  ||| S:858 E:864 ||| NN
of  ||| S:864 E:867 ||| IN
inclusion  ||| S:867 E:877 ||| JJ
age  ||| S:877 E:881 ||| NN
was  ||| S:881 E:885 ||| VBD
55-65 ||| S:885 E:890 ||| CD
.  ||| S:890 E:892 ||| .
No  ||| S:892 E:895 ||| DT
other  ||| S:895 E:901 ||| JJ
clinical  ||| S:901 E:910 ||| JJ
or  ||| S:910 E:913 ||| CC
metabolic  ||| S:913 E:923 ||| JJ
problems  ||| S:923 E:932 ||| NNS
were  ||| S:932 E:937 ||| VBD
present ||| S:937 E:944 ||| JJ
.  ||| S:944 E:946 ||| .
Meriva®  ||| S:946 E:954 ||| NNP
was  ||| S:954 E:958 ||| VBD
administered  ||| S:958 E:971 ||| VBN
at  ||| S:971 E:974 ||| IN
the  ||| S:974 E:978 ||| DT
dosage  ||| S:978 E:985 ||| NN
of  ||| S:985 E:988 ||| IN
2  ||| S:988 E:990 ||| CD
tablets ||| S:990 E:997 ||| CD
/ ||| S:997 E:998 ||| CD
day  ||| S:998 E:1002 ||| NN
( ||| S:1002 E:1003 ||| -LRB-
2  ||| S:1003 E:1005 ||| CD
x  ||| S:1005 E:1007 ||| SYM
500  ||| S:1007 E:1011 ||| CD
mg  ||| S:1011 E:1014 ||| NN
of  ||| S:1014 E:1017 ||| IN
Meriva® ||| S:1017 E:1024 ||| CD
/ ||| S:1024 E:1025 ||| CD
day ||| S:1025 E:1028 ||| NN
,  ||| S:1028 E:1030 ||| ,
corresponding  ||| S:1030 E:1044 ||| JJ
to  ||| S:1044 E:1047 ||| TO
2  ||| S:1047 E:1049 ||| CD
x  ||| S:1049 E:1051 ||| SYM
100  ||| S:1051 E:1055 ||| CD
mg  ||| S:1055 E:1058 ||| CD
curcumin ||| S:1058 E:1066 ||| CD
/ ||| S:1066 E:1067 ||| CD
day ||| S:1067 E:1070 ||| NN
)  ||| S:1070 E:1072 ||| -RRB-
with  ||| S:1072 E:1077 ||| IN
a  ||| S:1077 E:1079 ||| DT
compliance  ||| S:1079 E:1090 ||| NN
values  ||| S:1090 E:1097 ||| VBZ
>  ||| S:1097 E:1099 ||| CD
95 ||| S:1099 E:1101 ||| CD
%  ||| S:1101 E:1103 ||| NN
as  ||| S:1103 E:1106 ||| IN
evaluated  ||| S:1106 E:1116 ||| NN
by  ||| S:1116 E:1119 ||| IN
the  ||| S:1119 E:1123 ||| DT
number  ||| S:1123 E:1130 ||| NN
of  ||| S:1130 E:1133 ||| IN
tablets  ||| S:1133 E:1141 ||| NNS
used  ||| S:1141 E:1146 ||| VBN
according  ||| S:1146 E:1156 ||| VBG
to  ||| S:1156 E:1159 ||| TO
medical  ||| S:1159 E:1167 ||| JJ
recommendation ||| S:1167 E:1181 ||| NN
.  ||| S:1181 E:1183 ||| .
No  ||| S:1183 E:1186 ||| DT
other  ||| S:1186 E:1192 ||| JJ
drugs  ||| S:1192 E:1198 ||| NNS
or  ||| S:1198 E:1201 ||| CC
food  ||| S:1201 E:1206 ||| NN
supplement  ||| S:1206 E:1217 ||| NN
were  ||| S:1217 E:1222 ||| VBD
used  ||| S:1222 E:1227 ||| VBN
during  ||| S:1227 E:1234 ||| IN
the  ||| S:1234 E:1238 ||| DT
study ||| S:1238 E:1243 ||| NN
.  ||| S:1243 E:1245 ||| .
All  ||| S:1245 E:1249 ||| DT
IPSS  ||| S:1249 E:1254 ||| NNP
scores ||| S:1254 E:1260 ||| NNS
,  ||| S:1260 E:1262 ||| ,
with  ||| S:1262 E:1267 ||| IN
the  ||| S:1267 E:1271 ||| DT
exception  ||| S:1271 E:1281 ||| NN
of  ||| S:1281 E:1284 ||| IN
the  ||| S:1284 E:1288 ||| DT
stream  ||| S:1288 E:1295 ||| NN
weakness  ||| S:1295 E:1304 ||| NN
score  ||| S:1304 E:1310 ||| NN
in  ||| S:1310 E:1313 ||| IN
the  ||| S:1313 E:1317 ||| DT
BSM  ||| S:1317 E:1321 ||| NNP
group ||| S:1321 E:1326 ||| NN
,  ||| S:1326 E:1328 ||| ,
were  ||| S:1328 E:1333 ||| VBD
improved  ||| S:1333 E:1342 ||| VBN
( ||| S:1342 E:1343 ||| -LRB-
p  ||| S:1343 E:1344 ||| FW
< ||| S:1344 E:1345 ||| SYM
0.05  ||| S:1345 E:1350 ||| FW
vs.  ||| S:1350 E:1354 ||| FW
inclusion ||| S:1354 E:1363 ||| FW
)  ||| S:1363 E:1365 ||| -RRB-
in  ||| S:1365 E:1368 ||| IN
both  ||| S:1368 E:1373 ||| DT
groups ||| S:1373 E:1379 ||| NNS
.  ||| S:1379 E:1381 ||| .
The  ||| S:1381 E:1385 ||| DT
overall  ||| S:1385 E:1393 ||| JJ
results  ||| S:1393 E:1401 ||| NNS
in  ||| S:1401 E:1404 ||| IN
the  ||| S:1404 E:1408 ||| DT
Meriva®  ||| S:1408 E:1416 ||| JJ
group  ||| S:1416 E:1422 ||| NN
were  ||| S:1422 E:1427 ||| VBD
significantly  ||| S:1427 E:1441 ||| RB
better  ||| S:1441 E:1448 ||| JJR
than  ||| S:1448 E:1453 ||| IN
in  ||| S:1453 E:1456 ||| IN
the  ||| S:1456 E:1460 ||| DT
BSM-only  ||| S:1460 E:1469 ||| JJ
group  ||| S:1469 E:1475 ||| NN
( ||| S:1475 E:1476 ||| -LRB-
p  ||| S:1476 E:1477 ||| CD
< ||| S:1477 E:1478 ||| SYM
0.05 ||| S:1478 E:1482 ||| CD
) ||| S:1482 E:1483 ||| -RRB-
.  ||| S:1483 E:1485 ||| .
No  ||| S:1485 E:1488 ||| DT
side  ||| S:1488 E:1493 ||| NN
effects  ||| S:1493 E:1501 ||| NNS
were  ||| S:1501 E:1506 ||| VBD
recorded ||| S:1506 E:1514 ||| VBN
.  ||| S:1514 E:1516 ||| .
The  ||| S:1516 E:1520 ||| DT
quality  ||| S:1520 E:1528 ||| NN
of  ||| S:1528 E:1531 ||| IN
life  ||| S:1531 E:1536 ||| NN
improved  ||| S:1536 E:1545 ||| VBN
in  ||| S:1545 E:1548 ||| IN
both  ||| S:1548 E:1553 ||| DT
groups ||| S:1553 E:1559 ||| NNS
,  ||| S:1559 E:1561 ||| ,
but  ||| S:1561 E:1565 ||| CC
was  ||| S:1565 E:1569 ||| VBD
significantly  ||| S:1569 E:1583 ||| RB
better  ||| S:1583 E:1590 ||| JJR
in  ||| S:1590 E:1593 ||| IN
the  ||| S:1593 E:1597 ||| DT
Meriva®  ||| S:1597 E:1605 ||| JJ
group  ||| S:1605 E:1611 ||| NN
( ||| S:1611 E:1612 ||| -LRB-
p  ||| S:1612 E:1613 ||| CD
< ||| S:1613 E:1614 ||| SYM
0.01 ||| S:1614 E:1618 ||| CD
) ||| S:1618 E:1619 ||| -RRB-
.  ||| S:1619 E:1621 ||| .
There  ||| S:1621 E:1627 ||| EX
was  ||| S:1627 E:1631 ||| VBD
also  ||| S:1631 E:1636 ||| RB
a  ||| S:1636 E:1638 ||| DT
significantly  ||| S:1638 E:1652 ||| RB
more  ||| S:1652 E:1657 ||| RBR
important  ||| S:1657 E:1667 ||| JJ
decrease  ||| S:1667 E:1676 ||| NN
in  ||| S:1676 E:1679 ||| IN
clinical  ||| S:1679 E:1688 ||| JJ
and  ||| S:1688 E:1692 ||| CC
subclinical  ||| S:1692 E:1704 ||| JJ
episodes  ||| S:1704 E:1713 ||| NNS
of  ||| S:1713 E:1716 ||| IN
urinary  ||| S:1716 E:1724 ||| JJ
infections  ||| S:1724 E:1735 ||| NNS
and  ||| S:1735 E:1739 ||| CC
urinary  ||| S:1739 E:1747 ||| JJ
block  ||| S:1747 E:1753 ||| NN
in  ||| S:1753 E:1756 ||| IN
the  ||| S:1756 E:1760 ||| DT
Meriva®  ||| S:1760 E:1768 ||| JJ
group  ||| S:1768 E:1774 ||| NN
( ||| S:1774 E:1775 ||| -LRB-
p  ||| S:1775 E:1776 ||| CD
< ||| S:1776 E:1777 ||| SYM
0.01 ||| S:1777 E:1781 ||| CD
) ||| S:1781 E:1782 ||| -RRB-
.  ||| S:1782 E:1784 ||| .
In  ||| S:1784 E:1787 ||| IN
patients  ||| S:1787 E:1796 ||| NNS
with  ||| S:1796 E:1801 ||| IN
BPH ||| S:1801 E:1804 ||| NNP
,  ||| S:1804 E:1806 ||| ,
the  ||| S:1806 E:1810 ||| DT
addition  ||| S:1810 E:1819 ||| NN
of  ||| S:1819 E:1822 ||| IN
Meriva®  ||| S:1822 E:1830 ||| CD
to  ||| S:1830 E:1833 ||| TO
the  ||| S:1833 E:1837 ||| DT
standard  ||| S:1837 E:1846 ||| JJ
treatment  ||| S:1846 E:1856 ||| NN
contributed  ||| S:1856 E:1868 ||| VBD
to  ||| S:1868 E:1871 ||| TO
the  ||| S:1871 E:1875 ||| DT
reduction  ||| S:1875 E:1885 ||| NN
of  ||| S:1885 E:1888 ||| IN
signs  ||| S:1888 E:1894 ||| NNS
and  ||| S:1894 E:1898 ||| CC
symptoms  ||| S:1898 E:1907 ||| NNS
of  ||| S:1907 E:1910 ||| IN
the  ||| S:1910 E:1914 ||| DT
disease  ||| S:1914 E:1922 ||| NN
without  ||| S:1922 E:1930 ||| IN
causing  ||| S:1930 E:1938 ||| VBG
any  ||| S:1938 E:1942 ||| DT
significant  ||| S:1942 E:1954 ||| JJ
additional  ||| S:1954 E:1965 ||| JJ
side  ||| S:1965 E:1970 ||| NN
effect ||| S:1970 E:1976 ||| NN
.  ||| S:1976 E:1978 ||| .
This  ||| S:1978 E:1983 ||| DT
pilot  ||| S:1983 E:1989 ||| NN
experience  ||| S:1989 E:2000 ||| NN
suggests  ||| S:2000 E:2009 ||| VBZ
a  ||| S:2009 E:2011 ||| DT
potential  ||| S:2011 E:2021 ||| JJ
novel  ||| S:2021 E:2027 ||| NN
clinical  ||| S:2027 E:2036 ||| JJ
application  ||| S:2036 E:2048 ||| NN
of  ||| S:2048 E:2051 ||| IN
curcumin ||| S:2051 E:2059 ||| NN
,  ||| S:2059 E:2061 ||| ,
and  ||| S:2061 E:2065 ||| CC
further  ||| S:2065 E:2073 ||| JJ
studies  ||| S:2073 E:2081 ||| NNS
aimed  ||| S:2081 E:2087 ||| VBN
at  ||| S:2087 E:2090 ||| IN
selecting  ||| S:2090 E:2100 ||| VBG
the  ||| S:2100 E:2104 ||| DT
most  ||| S:2104 E:2109 ||| RBS
appropriate  ||| S:2109 E:2121 ||| JJ
dosages  ||| S:2121 E:2129 ||| NN
and  ||| S:2129 E:2133 ||| CC
length  ||| S:2133 E:2140 ||| NN
of  ||| S:2140 E:2143 ||| IN
treatment  ||| S:2143 E:2153 ||| NN
as  ||| S:2153 E:2156 ||| IN
well  ||| S:2156 E:2161 ||| RB
as  ||| S:2161 E:2164 ||| IN
the  ||| S:2164 E:2168 ||| DT
possibility  ||| S:2168 E:2180 ||| NN
to  ||| S:2180 E:2183 ||| TO
including  ||| S:2183 E:2193 ||| VBG
longer  ||| S:2193 E:2200 ||| JJR
treatments  ||| S:2200 E:2211 ||| NNS
will ||| S:2211 E:2215 ||| MD
,  ||| S:2215 E:2217 ||| ,
undoubtedly ||| S:2217 E:2228 ||| RB
,  ||| S:2228 E:2230 ||| ,
validate  ||| S:2230 E:2239 ||| NN
and  ||| S:2239 E:2243 ||| CC
optimize  ||| S:2243 E:2252 ||| VBG
the  ||| S:2252 E:2256 ||| DT
role  ||| S:2256 E:2261 ||| NN
of  ||| S:2261 E:2264 ||| IN
Meriva®  ||| S:2264 E:2272 ||| CD
in  ||| S:2272 E:2275 ||| IN
the  ||| S:2275 E:2279 ||| DT
management  ||| S:2279 E:2290 ||| NN
of  ||| S:2290 E:2293 ||| IN
BPH ||| S:2293 E:2296 ||| NNP
.  ||| S:2296 E:2298 ||| .
